Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Carmen Loquai, Lisa Zimmer et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 18
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – A multicenter study on 2419 patients from the prospective skin cancer registry ADORegJulian Kött, N. Devereux, Tim Zell et al.|European Journal of Cancer|2024Cited by 16
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanomaDirk Tomsitz, Lucie Heinzerling, Elisabeth Livingstone et al.|Journal of the European Academy of Dermatology and Venereology|2025Cited by 2
Sex differences and its impact on treatment outcomes of advanced melanoma in Germany – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREGAnna‐Sophia Leven, Selma Ugurel, T. J. Peters et al.|EJC Skin Cancer|2024Cited by 0
459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREGMaximilian Haist, Carmen Loquai, Henner Stege et al.|Regular and Young Investigator Award Abstracts|2023Cited by 0